Zealand and Beta Bionics to collaborate on the development of a first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes
June 10, 2016 09:00 ET
|
Zealand Pharma A/S
Synergistic match of Beta Bionics’s dual-hormonal, artificial, or bionic, pancreas device platform, the iLet, and Zealand’s novel liquid stable glucagon analog, ZP4207
An automated insulin +...
Zealand og Beta Bionics i samarbejde om udviklingen af et banebrydende, bi-hormonelt bugspytkirtelsystem til behandling af type 1-diabetikere
June 10, 2016 09:00 ET
|
Zealand Pharma A/S
Et synergistisk match mellem Beta Bionics’ kunstige (eller bioniske), bi-hormonelle bugspytkirtelsystem, benævnt iLet, og Zealands nye, flydende og stabile glukagon-analog ZP4207
Et...
Zealand informs of new data on iGlarLixi and proprietary preclinical peptide drug candidates to be presented at the 76th Annual American Diabetes Associations Scientific Sessions
June 08, 2016 15:39 ET
|
Zealand Pharma A/S
First time presentations at a scientific congress of results from the two pivotal Phase III trials, LixiLan-L and LixiLan-O, with iGlarLixi
Presentations in two oral sessions on Sunday, 12...
Zealand meddeler, at der præsenteres nye data vedrørende iGlarLixi og selskabets egne prækliniske peptidbaserede lægemiddelkandidater på den amerikanske diabetesforenings (ADA) 76. videnskabelige kongres
June 08, 2016 15:39 ET
|
Zealand Pharma A/S
For første gang præsenteres resultater fra de to fase III-studier LixiLan-O og LixiLan-L med iGlarLixi på en videnskabelig kongres
To mundtlige præsentationer finder sted på sessioner søndag...
Zealand announces information received from its major shareholder, Sunstone LSV Management A/S, and a related change to its Board of Directors
June 02, 2016 05:59 ET
|
Zealand Pharma A/S
A proposed voluntary liquidation of certain Sunstone managed funds during Q3 2016 will lead to the distribution of 13% of Zealand’s share capital to a broad group of institutional...
Zealand meddeler om information modtaget fra storaktionær, Sunstone LSV Management A/S, og om en relateret ændring i bestyrelsen
June 02, 2016 05:59 ET
|
Zealand Pharma A/S
En foreslået, frivillig opløsning af visse fonde forvaltet af Sunstone medfører i 3. kvartal 2016, at 13% af Zealands aktiekapital vil blive fordelt til en bred gruppe af institutionelle...
Zealand presents at international healthcare investor conferences in June 2016
June 01, 2016 15:46 ET
|
Zealand Pharma A/S
Copenhagen, 1 June 2016 – Zealand informs that its senior management will present the company and host investor meetings at the following healthcare investor conferences in June 2016, taking place...
Zealand præsenterer på internationale healthcare−investorkonferencer i juni 2016
June 01, 2016 15:46 ET
|
Zealand Pharma A/S
København, 1. juni 2016 – Zealand meddeler, at selskabets ledelse vil præsentere selskabet og afholde investormøder ved følgende healthcare-investorkonferencer, der afholdes i juni 2016 i...
Zealand annoncerer det samlede antal aktier og stemmerettigheder i selskabet pr. 31. maj 2016
May 31, 2016 07:50 ET
|
Zealand Pharma A/S
København, 31. maj 2016 – I henhold til § 6 i Bekendtgørelse om udsteders oplysningsforpligtelser meddeler Zealand det samlede antal aktier og stemmerettigheder i selskabet ved udgangen af en...
Zealand announces the total number of shares and voting rights in the company as of 31 May 2016
May 31, 2016 07:50 ET
|
Zealand Pharma A/S
Copenhagen, 31 May 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand announces the total number of shares and voting rights in the company...